Interpretation of the updates of the Chinese guidelines for the diagnosis and treatment of primary liver cancer (CNLC-2024 Edition)

Abstract

Additional randomized controlled studies and high-level evidence for the diagnosis and management of liver cancer patients have been published since the release of Diagnosis and Treatment of Primary Liver Cancer Guidelines (CNLC-2022 edition). The 2024 version algorithm was updated accordingly by the national expert committee for the standardization and homogenization of liver cancer diagnosis and treatment in China. In this review, with reference to the guidelines of the 2022 version, we interpreted the main update points of the 2024 version to facilitate the nationwide dissemination and implementation of the guidelines.

Keywords

Primary liver cancer / hepatocellular carcinoma / guidelines / update / interpretation

References

[1] Zheng RS,Han BF.Cancer incidence and mortality in China, 2022.Zhonghua Zhongliu Zazhi2024;46:221-31

[2] Zhou J,Wang Z.Guidelines for the diagnosis and treatment of primary liver cancer (2022 Edition).Liver Cancer2023;12:405-44

[3] Fan R,Sun J.aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis.J Hepatol2020;73:1368-78

[4] Chen L,Zheng B.PreCar TeamGenome-scale profiling of circulating cell-free DNA signatures for early detection of hepatocellular carcinoma in cirrhotic patients.Cell Res2021;31:589-92 PMCID:PMC8089097

[5] Fan R,Zhao S.Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures.J Hepatol2023;79:933-44

[6] Barr RG,Luo Y.Contrast-enhanced ultrasound imaging of the liver: a review of the clinical evidence for SonoVue and Sonazoid.Abdom Radiol (NY)2020;45:3779-88

[7] Lyshchik A,Bradigan K.CEUS LI-RADS Trial GroupContrast-enhanced ultrasound liver imaging reporting and data system: clinical validation in a prospective multinational study in North America and Europe.Hepatology2024;79:380-91

[8] Zhao CK,Pu YY.Response evaluation using contrast-enhanced ultrasound for unresectable advanced hepatocellular carcinoma treated with tyrosine kinase inhibitors plus Anti-PD-1 antibody therapy.Ultrasound Med Biol2024;50:142-9

[9] Huang YL,Zhu YL.Quantitative diagnosis of nonalcoholic fatty liver disease with ultrasound attenuation imaging in a biopsy-proven cohort.Acad Radiol2023;30 Suppl 1:S155-63

[10] Pung L,Mueller K.The role of cone-beam CT in transcatheter arterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis.J Vasc Interv Radiol2017;28:334-41

[11] Siripongsatian D,Kunawudhi A.Comparisons of quantitative parameters of ga-68-labelled fibroblast activating protein inhibitor (FAPI) PET/CT and [(18)F]F-FDG PET/CT in patients with liver malignancies.Mol Imaging Biol2022;24:818-29 PMCID:PMC9053129

[12] Lan L,Xu T.Prospective comparison of (68)Ga-FAPI versus (18)F-FDG PET/CT for tumor staging in biliary tract cancers.Radiology2022;304:648-57

[13] Piratvisuth T,Tanwandee T.Development and clinical validation of a novel algorithmic score (GAAD) for detecting HCC in prospective cohort studies.Hepatol Commun2023;7 PMCID:PMC10635602

[14] Yang T,Wang G.A novel online calculator based on serum biomarkers to detect hepatocellular carcinoma among patients with hepatitis B.Clin Chem2019;65:1543-53

[15] Zhou J,Gao X.Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma.J Clin Oncol2011;29:4781-8

[16] Lu XY,Lau WY.Hepatocellular carcinoma expressing cholangiocyte phenotype is a novel subtype with highly aggressive behavior.Ann Surg Oncol2011;18:2210-7

[17] Zhuo J,Lin Z.The distinct responsiveness of cytokeratin 19-positive hepatocellular carcinoma to regorafenib.Cell Death Dis2021;12:1084 PMCID:PMC8595883

[18] Chen L,Zhou Q.Microvascular invasion status and its survival impact in hepatocellular carcinoma depend on tissue sampling protocol.Ann Surg Oncol2021;28:6747-57

[19] Nara S,Sakamoto Y.Prognostic impact of marginal resection for patients with solitary hepatocellular carcinoma: evidence from 570 hepatectomies.Surgery2012;151:526-36

[20] Chin KM,Cheong CK.Outcomes after curative therapy for hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: a meta-analysis and review of current literature.HPB (Oxford)2021;23:1164-74

[21] Benedetto F, Magistri P, Di Sandro S, et al; Robotic HPB Study Group. Safety and efficacy of robotic vs open liver resection for hepatocellular carcinoma.JAMA Surg2023;158:46-54

[22] Wang Q,Dai XM,Zhu Z.Laparoscopic versus open liver resection for hepatocellular carcinoma in elderly patients: Systematic review and meta-analysis of propensity-score matched studies.Int J Surg2022;105:106821

[23] Ogata S,Farges O,Sibert A.Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma.Br J Surg2006;93:1091-8

[24] Hwang S,Ko GY.Preoperative sequential portal and hepatic vein embolization in patients with hepatobiliary malignancy.World J Surg2015;39:2990-8

[25] Dupré A,Peyrat P,Meeus P.Associating portal embolization and artery ligation to induce rapid liver regeneration in staged hepatectomy.Br J Surg2015;102:1541-50

[26] Glantzounis GK,Basourakos SP,Lianos GD.The role of portal vein embolization in the surgical management of primary hepatobiliary cancers. A systematic review.Eur J Surg Oncol2017;43:32-41

[27] Peng Y,Qu X.Transcatheter arterial embolization-salvaged ALPPS, a novel ALPPS procedure especially for patients with hepatocellular carcinoma and severe fibrosis/cirrhosis.Hepatobiliary Surg Nutr2022;11:504-14 PMCID:PMC9396088

[28] Famularo S,Cipriani F.ITALI.CA Group and HE.RC.O.LE.S. Group. Hepatectomy versus sorafenib in advanced nonmetastatic hepatocellular carcinoma: a real-life multicentric weighted comparison.Ann Surg2022;275:743-52

[29] Kokudo T,Matsuyama Y.Liver Cancer Study Group of JapanSurvival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion.J Hepatol2016;65:938-43

[30] Zhang XP,Chen ZH.An eastern hepatobiliary surgery hospital/portal vein tumor thrombus scoring system as an aid to decision making on hepatectomy for hepatocellular carcinoma patients with portal vein tumor thrombus: a multicenter study.Hepatology2019;69:2076-90

[31] Govalan R,Luu M.Comparison of surgical resection and systemic treatment for hepatocellular carcinoma with vascular invasion: national cancer database analysis.Liver Cancer2021;10:407-18 PMCID:PMC8527916

[32] Li B,Zheng Y.Conversion to resectability using transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for initially unresectable hepatocellular carcinoma.Ann Surg Open2021;2:e057 PMCID:PMC10455427

[33] Byun HK,Im YR,Han KH.Dose escalation by intensity modulated radiotherapy in liver-directed concurrent chemoradiotherapy for locally advanced BCLC stage C hepatocellular carcinoma.Radiother Oncol2019;133:1-8

[34] Yuan Y,Yang Z.TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study.Int J Surg2023;109:1222-30 PMCID:PMC10389515

[35] Tabrizian P,Mehta N.Ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma.JAMA Surg2022;157:779-88 PMCID:PMC9301590

[36] Chan AWH,Berhane S.Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection.J Hepatol2018;69:1284-93

[37] Wu JC,Chau GY.Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma.J Hepatol2009;51:890-7

[38] Imamura H,Tanaka E.Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.J Hepatol2003;38:200-7

[39] Li SH,Cheng Y.Postoperative adjuvant hepatic arterial infusion chemotherapy with folfox in hepatocellular carcinoma with microvascular invasion: a multicenter, phase III, randomized study.J Clin Oncol2023;41:1898-908 PMCID:PMC10082249

[40] Qin S,Cheng AL.IMbrave050 investigatorsAtezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.Lancet2023;402:1835-47

[41] Lee JH,Lim YS.Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.Gastroenterology2015;148:1383-91.e6

[42] He C,Li C.Thymalfasin, a promising adjuvant therapy in small hepatocellular carcinoma after liver resection.Medicine (Baltimore)2017;96:e6606 PMCID:PMC5406071

[43] Huang G,Lau WY.Antiviral therapy reduces hepatocellular carcinoma recurrence in patients with low hbv-dna levels: a randomized controlled trial.Ann Surg2018;268:943-54

[44] Wu J,Cao L.Adjuvant pegylated interferon therapy improves the survival outcomes in patients with hepatitis-related hepatocellular carcinoma after curative treatment: A meta-analysis.Medicine (Baltimore)2018;97:e11295 PMCID:PMC6076097

[45] Sapisochin G,Joo DJ.Long-term effects of everolimus-facilitated tacrolimus reduction in living-donor liver transplant recipients with hepatocellular carcinoma.Ann Transplant2022;27:e937988 PMCID:PMC9700399

[46] Wang Z,Zhang DZ.Microwave ablation versus laparoscopic resection as first-line therapy for solitary 3-5-cm HCC.Hepatology2022;76:66-77

[47] Miyayama S,Yamashiro M.Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil.J Vasc Interv Radiol2007;18:365-76

[48] de Baere T,Chung JW.Initiative on superselective conventional transarterial chemoembolization results (INSPIRE).Cardiovasc Intervent Radiol2022;45:1430-40 PMCID:PMC9499883

[49] Zhang YJ,Chen Y,Peng Z.Long-term outcomes of transcatheter arterial chemoembolization combined with radiofrequency ablation as an initial treatment for early-stage hepatocellular carcinoma.JAMA Netw Open2021;4:e2126992 PMCID:PMC8477266

[50] Morimoto M,Kondou M,Morita S.Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization.Cancer2010;116:5452-60

[51] Peng ZW,Chen MS.Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial.J Clin Oncol2013;31:426-32

[52] Wu JY,Bai YN.Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a multicenter retrospective study.J Hepatocell Carcinoma2021;8:1233-40 PMCID:PMC8502053

[53] Chiang CL,Chan KSK.Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial.Lancet Gastroenterol Hepatol2023;8:169-78

[54] Wang Q,Bai W.China HCC-TACE Study GroupDevelopment of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: a multicentre observational study.J Hepatol2019;70:893-903

[55] Wang Z,Bai W.Exploratory analysis to identify candidates benefitting from combination therapy of transarterial chemoembolization and sorafenib for first-line treatment of unresectable hepatocellular carcinoma: a multicenter retrospective observational study.Liver Cancer2020;9:308-25 PMCID:PMC7325128

[56] Zhu HD,Huang MS.CHANCE001 InvestigatorsTransarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001).Signal Transduct Target Ther2023;8:58

[57] Jin ZC,Chen JJ.CHANCE InvestigatorsReal-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study.Eur Radiol2023;33:8669-81 PMCID:PMC10667391

[58] Li S,Wu J.Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study.Front Immunol2023;14:1109771 PMCID:PMC9981935

[59] Xia D,Bai W.China HCC-TACE Study GroupOptimal time point of response assessment for predicting survival is associated with tumor burden in hepatocellular carcinoma receiving repeated transarterial chemoembolization.Eur Radiol2022;32:5799-810

[60] Kim BK,Park JY.Prospective comparison of prognostic values of modified response evaluation criteria in solid tumours with european association for the study of the liver criteria in hepatocellular carcinoma following chemoembolisation.Eur J Cancer2013;49:826-34

[61] Memon K,Lewandowski RJ.Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times.Gastroenterology2011;141:526-35, 535.e1 PMCID:PMC3152626

[62] Wei Z,Bi X.Neoadjuvant radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a systematic review.Hepatobiliary Surg Nutr2022;11:709-17 PMCID:PMC9577988

[63] Wu F,Dong D.Phase 2 evaluation of neoadjuvant intensity-modulated radiotherapy in centrally located hepatocellular carcinoma: a nonrandomized controlled trial.JAMA Surg2022;157:1089-96 PMCID:PMC9535533

[64] Chen J,Han Y,Su K.Clinical efficacy and safety of external radiotherapy combined with sorafenib in the treatment of hepatocellular carcinoma: a systematic review and meta-analysis.Ann Hepatol2022;27:100710

[65] Munoz-Schuffenegger P,Atenafu EG.Stereotactic body radiation therapy for hepatocellular carcinoma with Macrovascular invasion.Radiother Oncol2021;156:120-6

[66] Chang WI,Kim YJ,Jung YJ.Role of radiotherapy in Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma treated with sorafenib.J Gastroenterol Hepatol2022;37:387-94

[67] Li H,Chen J.External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis.Clin Exp Med2023;23:1537-49 PMCID:PMC10460724

[68] Brade AM,Brierley J.Phase 1 trial of sorafenib and stereotactic body radiation therapy for hepatocellular carcinoma.Int J Radiat Oncol Biol Phys2016;94:580-7

[69] Wang H,Zhao Y.Phase 1 trial of apatinib combined with intensity-modulated radiotherapy in unresectable hepatocellular carcinoma.BMC Cancer2022;22:771 PMCID:PMC9287866

[70] Huang Y,Liao W,Wang Z.Combination of sorafenib, camrelizumab, transcatheter arterial chemoembolization, and stereotactic body radiation therapy as a novel downstaging strategy in advanced hepatocellular carcinoma with portal vein tumor thrombus: a case series study.Front Oncol2021;11:650394 PMCID:PMC8366058

[71] Li J,Dong P.Immunotherapy of hepatocellular carcinoma: recent progress and new strategy.Front Immunol2023;14:1192506 PMCID:PMC10206122

[72] Kimura T,Kameoka T,Kariya S.The current role of stereotactic body radiation therapy (SBRT) in hepatocellular carcinoma (HCC).Cancers (Basel)2022;14:4383 PMCID:PMC9496682

[73] Zhong L,Peng W.Safety of PD-1/PD-L1 inhibitors combined with palliative radiotherapy and anti-angiogenic therapy in advanced hepatocellular carcinoma.Front Oncol2021;11:686621 PMCID:PMC8170410

[74] Chen YX,Du SS.Stereotactic body radiotherapy combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma: A phase II clinical trial.World J Gastroenterol2023;29:3871-82 PMCID:PMC10324536

[75] Song SH,Choi D,Park HC.Evaluation of early treatment response to radiotherapy for HCC using pre- and post-treatment MRI.Acta Radiol2019;60:826-35

[76] Gatti M,Darvizeh F.Role of gadoxetic acid-enhanced liver magnetic resonance imaging in the evaluation of hepatocellular carcinoma after locoregional treatment.World J Gastroenterol2022;28:3116-31 PMCID:PMC9331537

[77] Zhang H,Jiang L.Recent advances in systemic therapy for hepatocellular carcinoma.Biomark Res2022;10:3 PMCID:PMC8744248

[78] Qin S,Gu S.CARES-310 Study GroupCamrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.Lancet2023;402:1133-46

[79] Qin S,Meyer T.Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial.JAMA Oncol2023;9:1651-9 PMCID:PMC10557031

[80] Abou-Alfa GK,Kudo M.Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer).Future Oncol2023;19:2505-16

[81] Zhu AX,Yen CJ.REACH-2 study investigatorsRamucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol2019;20:282-96

[82] Finn RS,Ikeda M.IMbrave150 InvestigatorsAtezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.N Engl J Med2020;382:1894-905

[83] Finn RS,Ikeda M.IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).JCO2021;39:267-267

[84] Ren Z,Bai Y.ORIENT-32 study groupSintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.Lancet Oncol2021;22:977-90

[85] Qin S,Gu S.Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.J Clin Oncol2021;39:3002-11 PMCID:PMC8445562

[86] Kudo M,Qin S.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.Lancet2018;391:1163-73

[87] Llovet JM,Mazzaferro V.SHARP Investigators Study GroupSorafenib in advanced hepatocellular carcinoma.N Engl J Med2008;359:378-90

[88] Cheng AL,Chen Z.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.Lancet Oncol2009;10:25-34

[89] Qin S,Lim HY.Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.J Clin Oncol2013;31:3501-8

[90] Qin S,Liang J.Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study.Oncologist2014;19:1169-78 PMCID:PMC4221370

[91] Bruix J,Merle P.RESORCE InvestigatorsRegorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet2017;389:56-66

[92] Qin S,Gu S.Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.Lancet Gastroenterol Hepatol2021;6:559-68

[93] Xu J,Gu S.Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase II trial.Clin Cancer Res2021;27:1003-11

[94] Qin S,Meng Z.Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial.Lancet Oncol2020;21:571-80

[95] Shao G,Yuan X.Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study.EClinicalMedicine2022;54:101679 PMCID:PMC9562926

[96] Qin S,Fang W.Pembrolizumab versus placebo as second-line therapy in patients from asia with advanced hepatocellular carcinoma: a randomized, double-blind, phase III trial.J Clin Oncol2023;41:1434-43

[97] Ren Z,Abou-Alfa GK.Tislelizumab in patients with previously treated advanced hepatocellular carcinoma (RATIONALE-208): a multicenter, non-randomized, open-label, phase 2 trial.Liver Cancer2023;12:72-84 PMCID:PMC9982342

[98] Singal AG,Yarchoan M.AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.Hepatology2023;78:1922-65

[99] Benson AB,Abbott DE.Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology.J Natl Compr Canc Netw2021;19:541-65

[100] Association for the Study of the Liver. Electronic address: [e-mail], European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.J Hepatol2018;69:182-236

[101] Zhong BY,Sun JH.Prognostic performance of the china liver cancer staging system in hepatocellular carcinoma following transarterial chemoembolization.J Clin Transl Hepatol2023;11:1321-8 PMCID:PMC10500297

[102] Bruix J,Galle PR,Sangro B.Systemic treatment of hepatocellular carcinoma: An EASL position paper.J Hepatol2021;75:960-74